Exelixis, Inc. (NASDAQ:EXEL) Stock Position Reduced by Blair William & Co. IL

Blair William & Co. IL trimmed its position in Exelixis, Inc. (NASDAQ:EXEL) by 0.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 752,836 shares of the biotechnology company’s stock after selling 6,133 shares during the quarter. Blair William & Co. IL owned approximately 0.25% of Exelixis worth $16,916,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in EXEL. Norges Bank bought a new position in shares of Exelixis during the fourth quarter worth about $73,449,000. LSV Asset Management boosted its stake in Exelixis by 107.7% during the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after purchasing an additional 2,989,021 shares during the period. Los Angeles Capital Management LLC grew its position in Exelixis by 948.3% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock worth $58,240,000 after purchasing an additional 2,220,150 shares during the last quarter. Jupiter Asset Management Ltd. increased its stake in shares of Exelixis by 148.2% in the first quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock valued at $53,817,000 after purchasing an additional 1,354,062 shares during the period. Finally, Swedbank AB bought a new stake in shares of Exelixis during the first quarter valued at approximately $22,455,000. 85.27% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on EXEL shares. Truist Financial restated a “buy” rating and issued a $33.00 target price (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Oppenheimer reissued an “outperform” rating and set a $29.00 price target on shares of Exelixis in a report on Tuesday, July 30th. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research note on Wednesday. JMP Securities increased their target price on shares of Exelixis from $27.00 to $29.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 7th. Finally, UBS Group assumed coverage on shares of Exelixis in a research report on Thursday. They set a “neutral” rating and a $30.00 price target on the stock. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average price target of $27.67.

Insider Activity at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 20,000 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.79, for a total transaction of $515,800.00. Following the sale, the executive vice president now owns 630,325 shares in the company, valued at approximately $16,256,081.75. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Jeffrey Hessekiel sold 20,000 shares of Exelixis stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.79, for a total value of $515,800.00. Following the transaction, the executive vice president now directly owns 630,325 shares of the company’s stock, valued at $16,256,081.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 125,000 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the sale, the chief financial officer now owns 721,680 shares in the company, valued at approximately $19,622,479.20. The disclosure for this sale can be found here. Insiders sold 302,858 shares of company stock worth $7,980,629 in the last quarter. 2.85% of the stock is owned by company insiders.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $26.83 on Friday. The stock has a market capitalization of $8.13 billion, a price-to-earnings ratio of 41.92, a PEG ratio of 0.58 and a beta of 0.54. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $27.83. The company has a 50 day moving average price of $25.04 and a 200 day moving average price of $23.29.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.44. The business had revenue of $637.18 million during the quarter, compared to analyst estimates of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. On average, sell-side analysts expect that Exelixis, Inc. will post 1.54 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.